Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JAAX | ISIN: US15102K1007 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:59
12,480 US-Dollar
+3,91 % +0,470
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELCUITY INC Chart 1 Jahr
5-Tage-Chart
CELCUITY INC 5-Tage-Chart

Aktuelle News zur CELCUITY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.06.Celcuity Inc. - S-8, Securities to be offered to employees in employee benefit plans2
15.05.Celcuity Inc. - 10-Q, Quarterly Report1
15.05.Celcuity outlines $2B peak revenue potential for gedatolisib as Phase 3 breast cancer trials progress1
14.05.Celcuity Inc. - 8-K, Current Report1
14.05.Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update52The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment...
► Artikel lesen
01.04.Stifel maintains Celcuity stock Buy rating, $42 target1
01.04.Celcuity projects $2B revenue potential for gedatolisib in second-line breast cancer market1
31.03.Celcuity Inc. - 10-K, Annual Report2
CELCUITY Aktie jetzt für 0€ handeln
31.03.Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update73The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025Presented encouraging...
► Artikel lesen
31.03.Celcuity Inc. - 8-K, Current Report1
28.03.An Overview of Celcuity's Earnings1
11.12.24Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium146Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with...
► Artikel lesen
14.11.24Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update151The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash equivalents...
► Artikel lesen
14.08.24Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update185Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1